Contribute to the
White Paper
The Oncothera White Paper is an initiative of Oncothera. The purpose of the white paper is to make an assessment of the current ecosystem for theranostics in Australia and from this paper make recommendations on how to improve patient accessibility.
​
We are currently seeking expressions of interest from radio-pharmaceutical organisations, specialist medical individuals and those involved in patient organisations. Our aim is to capture the current state of theranostics in Australia, review available treatments, with a focus on patient access, as well as planning for the future of theranostics and oncology.
Unveiling the Future: The Power of Theranostics in Modern Medicine
The contents of this White Paper will include the following key topics (and more!)
Introduction to Theranostics
Define theranostics and its role in modern medicine, highlighting its potential to revolutionize diagnostics and treatment.
Emerging Technologies and Innovations
Highlight recent advancements in theranostic technologies, such as nanoparticle-based imaging agents, targeted drug delivery systems, and molecular biomarkers.
Advantages of Theranostics
Discuss the benefits of theranostics over traditional diagnostic and treatment methods, including improved accuracy, personalized treatment plans, and reduced side effects.
Clinical Case Studies
Present real-world examples of successful theranostic interventions, demonstrating their efficacy in improving patient outcomes and quality of life.
Applications Across Medical Fields
Explore the diverse applications of theranostics in various medical specialties, such as oncology, cardiology, neurology, and infectious diseases.
Future Directions and Challenges
Discuss the potential barriers to widespread adoption of theranostics, as well as future research directions and opportunities for collaboration between academia, industry, and healthcare providers.
Expression of interest
That's great you're interested in contributing to this first-of-its-kind White Paper, by Oncothera Advocacy.
​
The lead author(s) of this White Paper will be staff of Oncothera Advocacy (.org) and members of the steering committee. During the draft writing process we would like to seek input from industry professionals and relevant organisations – so we can be confident to capture an accurate and thorough snapshot of theranostics, radio-pharma and oncology therapy areas in Australia. External input would be greatly appreciated at this stage – and all contributors will be accredited appropriately.
We very much appreciate all the time and effort from all contributors, however there will be no financial payment for any input – this White Paper is for the benefit of the entire category, and ultimately designed to benefit patients by influencing greater access to treatments.
​
If you're interested in contributing to this ground-breaking White Paper, please take a moment to fill out the form and we'll be in touch to discuss your potential participation.